Emmanuel Macron and Marine Le Pen to face each other in runoffWorld April 24, 8:13
Danish defense minister accuses Russians of hacking into his staff’s emailsWorld April 24, 7:50
PROFILE: Emmanuel Macron poised to become France’s youngest presidentWorld April 24, 6:44
North Korea ready to carry out nuclear test at any time — expertsWorld April 24, 5:56
Swedish think tank puts Russia in world’s top three biggest defense spendersMilitary & Defense April 24, 4:35
Ukraine reconciliation meeting in Minsk postponed over OSCE car blastWorld April 24, 3:21
Macron announces his victory in first round of French presidential voteWorld April 24, 1:29
Le Pen gets 23.08%, Macron - 23.11% after 33 mln votes counted — Interior MinistryWorld April 23, 23:58
Preliminary results of French polls reveal defeat of two leading partiesWorld April 23, 22:49
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.